[The therapeutic effect of @entity4258 on XXXX ].

@entity1 @entity32 @entity1069 @entity4258 @entity5938 @entity794 @entity7264 @entity797 @entity21 @entity526 @entity5939
The clinical efficacy of @entity4258 ( @entity7264 ) was evaluated in 74 @entity1 having @entity1069 with the subjective symptoms suggesting the @entity32 of prostate and more than five white bloodcells (WBCs)/hpf in their prostatic secretions ( @entity21 ). Of these, gram negative rods with greater than or equal to 10(3)CFU/ml (GNR group) were isolated from the @entity21 in 10 @entity1 (13.6%) and gram positive cocci with greater than or equal to 10(3) CFU/ml (GPC group) were obtained in 46 @entity1 (62.2%). @entity526 (70.0%) was the most frequent strain isolated among GNR group and @entity5938 (40.4%), @entity794 (19.1%), @entity797 (17.0%) and @entity5939 (14.9%) were frequently isolated among the GPC group. The overall clinical efficacy of @entity7264 was determined at the second and fourth week by the three factors, (1) the effect on bacteria, (2) WBCs in the @entity21 and (3) the subjective symptoms in the @entity1 with bacteria of greater than or equal to 10(3) CFU/ml being isolated. The overall clinical effectiveness rate was 71.4% and 100%, respectively, in the GNR group. In the GPC group, its rate was 79.3% and 88.0%, respectively. The @entity1 with no bacteria or less than 10(3) CFU/ml isolated from the @entity21 had an overall clinical effectiveness rate of 89.8% at the second week and 90.0% at the fourth, when it was evaluated by the effect on WBCs and subjective symptoms. In the effect of @entity7264 on bacteria in the @entity21 , it eliminated them in 75.0% and 83.9% at the second and fourth week, respectively, of all @entity1 with GNR or GPC of greater than or equal to 10(3) CFU/ml isolated from the @entity21 . The minimum inhibitory concentrations (MIC) of @entity7264 against @entity526 isolated from the @entity21 was distributed from 0.025 microgram/ml to 3.13 micrograms/ml with most below 0.1 microgram/ml. Those against all other GNR were below 0.78 microgram/ml. @entity7264 showed good antimicrobial activities against GPC with most of MIC being distributed from 0.78 microgram/ml to 1.56 micrograms/ml. @entity7264 produced the highest eradication rate in bacteriological response not only against GNR such as 100% at the first, the second and fourth week but GPC as 89.2%, 93.8% and 96.0%, respectively. In the effect of @entity7264 on WBCs in @entity21 , 40-50% of @entity1 got free from the inflammation of prostate by @entity7264 treatment. This became prominent in the GNR group as the treatment was continued although not in the GPC group. The subjective symptoms were improved by @entity7264 treatment in most of the @entity1 .
